CAR T Cells: Cancer Cell Surface Receptors Are the Target for Cancer Therapy

被引:7
|
作者
Shademan, Behrouz [1 ]
Karamad, Vahidreza [1 ]
Nourazarian, Alireza [2 ]
Avci, Cigir Biray [1 ]
机构
[1] EGE Univ, Fac Med, Dept Med Biol, Izmir, Turkey
[2] Tabriz Univ Med Sci, Fac Med, Dept Biochem & Clin Labs, Tabriz, Iran
关键词
CAR-T cell; Immunotherapy; Surface receptors; Tumor microenvironment; CHIMERIC-ANTIGEN-RECEPTOR; ACUTE MYELOID-LEUKEMIA; ANTITUMOR-ACTIVITY; STEM-CELLS; CD19; CAR; IMMUNOTHERAPY; MESOTHELIN; CHEMOTHERAPY; MALIGNANCIES; PERSISTENCE;
D O I
10.34172/apb.2022.051
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Immunotherapy has become a prominent strategy for the treatment of cancer. A method that improves the immune system's ability to attack a tumor (Enhances antigen binding). Targeted killing of malignant cells by adoptive transfer of chimeric antigen receptor (CAR) T cells is a promising immunotherapy technique in the treatment of cancers. For this purpose, the patient's immune cells, with genetic engineering aid, are loaded with chimeric receptors that have particular antigen binding and activate cytotoxic T lymphocytes. That increases the effectiveness of immune cells and destroying cancer cells. This review discusses the basic structure and function of CAR-T cells and how antigenic targets are identified to treat different cancers and address the disadvantages of this treatment for cancer.
引用
收藏
页码:476 / 489
页数:14
相关论文
共 50 条
  • [1] CAR T-Cell Cancer Therapy Targeting Surface Cancer/Testis Antigens
    Jakobsen, Mie K.
    Gjerstorff, Morten F.
    [J]. FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [2] Immunogenicity of CAR T cells in cancer therapy
    Wagner, Dimitrios L.
    Fritsche, Enrico
    Pulsipher, Michael A.
    Ahmed, Nabil
    Hamieh, Mohamad
    Hegde, Meenakshi
    Ruella, Marco
    Savoldo, Barbara
    Shah, Nirali N.
    Turtle, Cameron J.
    Wayne, Alan S.
    Abou-el-Enein, Mohamed
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2021, 18 (06) : 379 - 393
  • [3] Immunogenicity of CAR T cells in cancer therapy
    Dimitrios L. Wagner
    Enrico Fritsche
    Michael A. Pulsipher
    Nabil Ahmed
    Mohamad Hamieh
    Meenakshi Hegde
    Marco Ruella
    Barbara Savoldo
    Nirali N. Shah
    Cameron J. Turtle
    Alan S. Wayne
    Mohamed Abou-el-Enein
    [J]. Nature Reviews Clinical Oncology, 2021, 18 : 379 - 393
  • [4] CAR T-cells for cancer therapy
    Muhammad, Niaz
    Mao, Qinwen
    Xia, Haibin
    [J]. BIOTECHNOLOGY AND GENETIC ENGINEERING REVIEWS, VOL 33, ISSUE 2, 2017, 33 (02): : 190 - 226
  • [5] CAR T Cells Activate Cancer Therapy
    Leslie, Mitch
    [J]. CANCER DISCOVERY, 2022, 12 (03) : 592 - 592
  • [6] Allogeneic CAR T Cell Therapy for Cancer
    Sasu, Barbra Johnson
    Lauron, Elvin James
    Schulz, Thomas
    Cheng, Hsin-Yuan
    Sommer, Cesar
    [J]. ANNUAL REVIEW OF CANCER BIOLOGY, 2024, 8 : 227 - 243
  • [7] A Novel Chimeric Antigen Receptor T Cell (CAR T) Therapy Target for Breast Cancer
    Williams, A. D.
    Posey, A.
    Tchou, J.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2018, 25 : S52 - S52
  • [8] CAR-T Cells in the Treatment of Ovarian Cancer: A Promising Cell Therapy
    Zhang, Xi-Wen
    Wu, Yi-Shi
    Xu, Tian-Min
    Cui, Man-Hua
    [J]. BIOMOLECULES, 2023, 13 (03)
  • [9] Born to survive: how cancer cells resist CAR T cell therapy
    Jean Lemoine
    Marco Ruella
    Roch Houot
    [J]. Journal of Hematology & Oncology, 14
  • [10] Born to survive: how cancer cells resist CAR T cell therapy
    Lemoine, Jean
    Ruella, Marco
    Houot, Roch
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)